from MSUK: Temelimab passes phase IIb
https://www.ms-uk.org/angel-ms-phase-2b ... melimab-ms
ANGEL-MS Phase 2b extension study confirms and extends the neuroprotective effects of temelimab in MS
GeNeuro, a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), has announced positive results from the ANGEL-MS study of its lead product, temelimab in MS.
Temelimab is a humanised, monoclonal antibody designed to neutralize pHERV-W, a pathogenic protein thought to be a causal factor in the development of MS.
The ANGEL-MS data confirmed that treatment with temelimab for two years had a continued, positive impact on key MRI measures of disease progression in MS patients, confirming and extending the data reported at Week 48 in the CHANGE-MS Phase 2b study. This includes reductions in brain atrophy, particularly in the cortex and thalamus, and maintenance in myelin integrity, as measured by magnetization transfer ratio (MTR) imaging. Importantly, for the first time, encouraging dose-dependent effects were seen on clinical measures of disease progression. This has been evidenced by a lower proportion of patients with 12-week confirmed EDSS progression, or with 20% worsening in 25-foot timed walk